PST-611 is a first in class non-viral vectorized therapy for the treatment of dry AMD/GA coding for human transferrin, a highly potent iron chelator, thus restoring normal iron homeostasis. During his ...

Developed by Ascentage Pharma, olverembatinib is the first China -approved third-generation BCR:ABL1 inhibitor, currently being jointly commercialized in China by Ascentage Pharma and Innovent ...

Biomarker research in dentistry is an emerging field that holds significant promise for transforming diagnostic and ...

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, is saddened to ...

According to the company, the oral presentation will detail results from the dose-escalation portion of the study.

Syndax (SNDX) announced that multiple abstracts evaluating revumenib, an oral small molecule menin inhibitor, have been accepted for oral ...

Mechelen, Belgium; November 5, 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will present new data from its CAR T- and TCR T-cell therapy pipeline at the 66th ...

No matter whether patients had CAD or not, the simpler regimen was linked to less mortality and major bleeding at 6 months.

The New Drug Application (NDA) for revumenib, an oral menin inhibitor, for the treatment of adult and pediatric relapsed or refractory (R/R) KMT2A-rearranged (KMT2Ar) acute leukemia was granted ...

DRI Healthcare Trust is also making a $5 million investment in KalVista, a biopharmaceutical company based in Cambridge, Massachusetts.